CYTOKINE RELEASE SYNDROME
Clinical trials for CYTOKINE RELEASE SYNDROME explained in plain language.
Never miss a new study
Get alerted when new CYTOKINE RELEASE SYNDROME trials appear
Sign up with your email to follow new studies for CYTOKINE RELEASE SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Old drug tested to tame dangerous side effects of Cutting-Edge cancer treatments
Disease control Recruiting nowThis early-stage study is testing if an existing drug called methylene blue can help control severe side effects that sometimes occur after powerful cancer immunotherapies like CAR-T. The side effects, called CRS and ICANS, involve dangerous immune system overreactions and neurol…
Matched conditions: CYTOKINE RELEASE SYNDROME
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New drug aims to tame dangerous side effects of powerful cancer treatment
Symptom relief Recruiting nowThis study is testing a new drug called CTO1681 to see if it can prevent or reduce severe side effects, specifically cytokine release syndrome (CRS), in adults with a type of lymphoma called DLBCL. Participants are people scheduled to receive a powerful cancer treatment called CA…
Matched conditions: CYTOKINE RELEASE SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: CytoAgents, Inc. • Aim: Symptom relief
Last updated Apr 01, 2026 14:42 UTC
-
AI-Guided home rehab aims to ease tough recovery from advanced cancer treatment
Symptom relief Recruiting nowThis study is testing a home-based recovery program for people with lymphoma or myeloma who are undergoing CAR-T cell therapy. The program uses a tablet or smartphone to guide patients through personalized exercise, nutrition, and counseling plans from home. The main goal is to s…
Matched conditions: CYTOKINE RELEASE SYNDROME
Phase: NA • Sponsor: University of Utah • Aim: Symptom relief
Last updated Mar 31, 2026 12:11 UTC